A. Fischer

发表

Interstitial lung disease in connective tissue disorders

A. Fischer, R. D. Bois, R. Bois, 2012, The Lancet.

Rheumatoid arthritis-interstitial lung disease-associated mortality.

G. Raghu, K. Brown, A. Fischer, 2011, American journal of respiratory and critical care medicine.

Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease

Jonathan H. Chung, K. Brown, S. K. Frankel, 2015, European Respiratory Journal.

Rheumatoid Arthritis–Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality

A. Fischer, K. Raimundo, J. Solomon, 2018, The Journal of Rheumatology.

Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease–Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities

D. Lynch, Joyce S Lee, G. Raghu, 2019, Arthritis & rheumatology.

D. Lynch, Joyce S Lee, G. Raghu, 2019, Arthritis & Rheumatology.

Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients

J. Park, A. Fischer, M. Cardiel, 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

J. Goldin, L. Lancaster, T. Maher, 2021, BMJ Open Respiratory Research.

LPA

A. Fischer, B. Decato, S. Palmer, 2020, Encyclopedia of Personality and Individual Differences.

Interstitial Lung Disease in Undifferentiated Forms of Connective Tissue Disease

K. Brown, A. Fischer, 2015, Arthritis care & research.

Pulmonary fibrosis in connective tissue disease (CTD): urgent challenges and opportunities.

A. Fischer, S. Donnelly, 2017, QJM : monthly journal of the Association of Physicians.

Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.

D. Lynch, K. Brown, S. K. Frankel, 2006, Chest.

Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease.

D. Lynch, Richard J Martin, R. D. du Bois, 2012, Respiratory medicine.

Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease

R. D. du Bois, K. Brown, S. K. Frankel, 2013, The Journal of Rheumatology.

Connective Tissue Disease-related Thoracic Disease.

D. Lynch, A. Fischer, J. Solomon, 2015, Clinics in chest medicine.

Update in the diagnosis and management of pulmonary vasculitis.

K. Brown, S. K. Frankel, G. Cosgrove, 2006, Chest.

Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives

P. Ferrari, A. Fischer, S. Studer, 2013, European Respiratory Review.

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management

M. Kreuter, V. Cottin, M. Wijsenbeek, 2019, Current medical research and opinion.

Fibrosing interstitial lung diseases: knowns and unknowns

S. Harari, V. Cottin, A. Fischer, 2019, European Respiratory Review.

It takes a village to care for the patient with idiopathic pulmonary fibrosis

A. Fischer, 2018, Cleveland Clinic Journal of Medicine.

Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease.

Joyce S Lee, H. Collard, K. Jones, 2017, Respiratory medicine.

Interstitial pneumonia with autoimmune features: the new consensus-based definition for this cohort of patients should be broadened

H. Collard, V. Cottin, A. Fischer, 2016, European Respiratory Journal.

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial

G. Raghu, D. Khanna, A. Fischer, 2016, The Journal of Rheumatology.

Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease

Joyce S Lee, A. Fischer, Joyce S. Lee, 2016, Expert review of clinical immunology.

Characterisation of patients with interstitial pneumonia with autoimmune features

Jonathan H. Chung, I. Noth, M. Strek, 2016, European Respiratory Journal.

Interstitial Lung Disease Evaluation: Detecting Connective Tissue Disease

Joyce S Lee, V. Cottin, A. Fischer, 2015, Respiration.

ANCA-associated renal vasculitis and acute exacerbation of scleroderma-associated interstitial lung disease: A case report

E. F. Kern, A. Fischer, S. Chartrand, 2015 .

Idiopathic Interstitial Pneumonia and Connective Tissue Disease-Associated Interstitial Lung Disease: Similarities and Differences

A. Fischer, J. Solomon, 2014 .

Interstitial Lung Disease 2 Interstitial lung disease in connective tissue disorders

A. Fischer, 2012 .

The impact of pulmonary arterial hypertension ( PAH ) on the lives of patients and carers : results from an international survey

P. Ferrari, A. Fischer, S. Studer, 2012 .

Pericardial abnormalities predict the presence of echocardiographically defined pulmonary arterial hypertension in systemic sclerosis-related interstitial lung disease.

D. Lynch, D. Curran‐Everett, K. Brown, 2007, Chest.

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

G. Raghu, M. Mayes, T. Maher, 2019, The New England journal of medicine.

Assessment and management of connective tissue disease-associated interstitial lung disease.

A. Fischer, S. Chartrand, 2015, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

Evaluation of Lung Disease in Patients with Connective Tissue Disease

K. Brown, A. Fischer, 2014 .

CHAPTER 45 – Lung

A. Fischer, R. D. Bois, R. Bois, 2011 .

Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease

K. Brown, S. K. Frankel, A. Fischer, 2009 .

State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances

C. Vancheri, A. Fischer, D. Sambataro, 2018, European Respiratory Review.

Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial

R. Elashoff, F. Martinez, M. Roth, 2016, The Lancet. Respiratory medicine.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial

M. Kreuter, V. Cottin, T. Maher, 2018, BMJ Open Respiratory Research.

The Lung in Systemic Lupus Erythematosus

A. Fischer, R. D. Bois, S. Chartrand, 2016 .

Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

J. Myers, K. Brown, J. Ryu, 2013, Respiratory medicine.

Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia.

G. Downey, R. D. du Bois, K. Brown, 2009, Respiratory medicine.

Interstitial lung disease: a rheumatologist's perspective.

A. Fischer, 2009, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease.

D. Lynch, R. D. du Bois, K. Brown, 2009, Chest.

Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival.

D. Lynch, K. Brown, S. Groshong, 2008, Chest.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.

M. Kreuter, V. Cottin, T. Maher, 2020, The Lancet. Respiratory medicine.

Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience

Joyce S Lee, A. Fischer, J. Swigris, 2019, Lung.

Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases

Augustine S. Lee, Joyce S Lee, E. Matteson, 2019, Mayo Clinic proceedings.

Update on morbidity and mortality in systemic sclerosis–related interstitial lung disease

A. Fischer, E. Volkmann, 2020, Journal of scleroderma and related disorders.

Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases

A. Fischer, J. Distler, 2019, Clinical Rheumatology.

Cross-Disciplinary Collaboration in Connective Tissue Disease-Related Lung Disease

L. Richeldi, A. Fischer, 2014, Seminars in Respiratory and Critical Care Medicine.

Connective tissue disease-associated interstitial lung disease: a call for clarification.

S. West, R. D. du Bois, K. Brown, 2010, Chest.

Practical approach to screening for scleroderma‐associated pulmonary arterial hypertension

V. Steen, A. Fischer, T. Bull, 2012, Arthritis care & research.

Pulmonary and thrombotic manifestations of systemic lupus erythematosus.

K. Brown, A. Fischer, J. Swigris, 2008, Chest.

Anti–Citrullinated Protein Antibodies Are Associated With Neutrophil Extracellular Traps in the Sputum in Relatives of Rheumatoid Arthritis Patients

J. Norris, M. Weisman, V. Holers, 2017, Arthritis & rheumatology.

Interstitial lung disease in suggestive forms of connective tissue disease Doença intersticial pulmonar em formas sugestivas de doença do tecido conectivo

A. Fischer, 2013 .

Interstitial lung disease in suggestive forms of connective tissue disease

A. Fischer, 2013, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

Pulmonary vasculitis as the first manifestation of rheumatoid arthritis

A. Fischer, Olga Tourin, Salvador de la Torre Carazo, 2012, Respiratory medicine case reports.

Management of connective tissue disease-associated interstitial lung disease.

A. Fischer, S. Chartrand, 2015, Rheumatic diseases clinics of North America.

A Practical Approach to Connective Tissue Disease-Associated Lung Disease

A. Fischer, R. D. Bois, R. Bois, 2012 .

Systemic Lupus Erythematosus-Related Interstitial Lung Disease

V. Strand, A. Fischer, J. Swigris, 2010 .

Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.

R. Simms, R. Domsic, M. Gomberg-Maitland, 2014, Clinical and experimental rheumatology.

Rheumatoid Arthritis and Pneumoconiosis

G. Raghu, K. Brown, A. Fischer, 2012 .

Diffuse Cystic Lung Disease as the Presenting Manifestation of Sjögren Syndrome.

N. Gupta, K. Wikenheiser-Brokamp, A. Fischer, 2016, Annals of the American Thoracic Society.

Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study.

M. Mayes, D. Furst, R. Simms, 2014, Seminars in arthritis and rheumatism.

Recent‐onset systemic lupus erythematosus complicated by acute respiratory failure

S. West, A. Fischer, K. Deane, 2013, Arthritis care & research.

Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD).

Ami A. Shah, A. Orbai, V. Strand, 2015, Current respiratory medicine reviews.

Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease.

S. West, K. Brown, C. Feghali-Bostwick, 2006, Chest.

Interstitial lung abnormalities in rheumatoid arthritis are common and important.

G. Cosgrove, A. Fischer, 2014, Chest.

A Rheumatologist’s Perspective

A. Fischer, 2009 .

Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry

M. Mayes, D. Furst, R. Domsic, 2012, Annals of the rheumatic diseases.

Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.

S. Nathan, C. Denton, A. Fischer, 2016, Respiratory medicine.

for the development of autoimmunity B-cell population is important + TLR7-driven accumulation of a novel CD11c

P. Marrack, J. Kappler, A. Fischer, 2012 .

LPA

A. Fischer, B. Decato, S. Palmer, 2020, Encyclopedia of Personality and Individual Differences.

Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry

D. Furst, R. Simms, J. Gordon, 2014, Arthritis care & research.

Tumor necrosis factor-alpha at the intersection of mycobacterial immunity and pathogenesis: an important new address in medicine.

A. Fischer, M. Iseman, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Interstitial Pneumonia with Autoimmune Features.

A. Fischer, 2019, Clinics in chest medicine.

Advocating for early interstitial lung disease detection in mixed connective tissue disease.

A. Fischer, B. Graney, 2018, Rheumatology.

Connective Tissue Disease-Associated Interstitial Lung Disease A Call for Clariﬁ cation

S. West, K. Brown, A. Fischer, 2010 .

SAT0442 Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary Hypertension: FVC, Outcomes and Survival- Observations from the Pulmonary Hypertension Recognition and Outcomes in Scleroderma (Pharos) Cohort

L. Saketkoo, V. Steen, A. Fischer, 2015 .

Reflux and autoimmunity: common links among patients with pulmonary fibrosis?

S. West, K. Brown, C. Feghali-Bostwick, 2007, Chest.

All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement

A. Fischer, K. Raimundo, J. Swigris, 2017, The Journal of Rheumatology.

Oxygen Administration and the Protection of Health-Care Workers From Infections

K. Brown, A. Fischer, R. Meehan, 2007 .

Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis.

S. West, K. Brown, C. Feghali-Bostwick, 2006, The Journal of rheumatology.

Primary care assessment of capillaroscopy abnormalities in patients with Raynaud’s phenomenon

M. Murtaugh, Rebecca S. Overbury, A. Fischer, 2015, Clinical Rheumatology.

Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-γ autoantibody.

E. Chan, L. Lenz, S. K. Frankel, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Trial Patients with Scleroderma-associated Interstitial Lung Disease : the LOTUSS An Open-label , Phase II Study of the Safety and Tolerability of Pirfenidone in

G. Raghu, A. Fischer, J. Seibold, 2016 .

Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry

M. Mayes, D. Furst, R. Simms, 2018, The Journal of Rheumatology.

Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c⁺ B-cell population is important for the development of autoimmunity.

P. Marrack, J. Kappler, A. Fischer, 2011, Blood.

Radiologic vignette: Hughes-Stovin syndrome.

S. West, A. Fischer, David S Korman, 2005, Arthritis and rheumatism.

Review of local wound management for scleroderma-associated digital ulcers

A. Fischer, T. Frech, V. Shanmugam, 2018, Journal of scleroderma and related disorders.

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease

M. Nalls, C. Blauwendraat, D. Schwartz, 2018, The New England journal of medicine.

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features

D. Lynch, H. Collard, I. Noth, 2015, European Respiratory Journal.

Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention

A. Fischer, N. Patel, E. Volkmann, 2019, Open access rheumatology : research and reviews.

Lung Disease in Rheumatoid Arthritis

A. Fischer, Joyce S. Lee, 2018, Respiratory Medicine.

A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease.

H. Collard, E. Matteson, K. Brown, 2014, Chest.

Connective Tissue Disease-Associated Interstitial Lung Disease

A. Fischer, J. Solomon, 2015, Journal of intensive care medicine.

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials

Ami A. Shah, R. Hubbard, W. Dixon, 2013, Thorax.

Recent advances in connective tissue disease related interstitial lung disease

Y. Kondoh, A. Suzuki, A. Fischer, 2017, Expert review of respiratory medicine.

Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.

A. Fischer, J. Swigris, S. Chartrand, 2016, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

Interstitial Pneumonia with Autoimmune Features

A. Fischer, B. Graney, 2019, Annals of the American Thoracic Society.

Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.

D. Furst, R. Simms, J. Gordon, 2017, Clinical and experimental rheumatology.

Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis

A. Fischer, Zheng-Yi Zhou, Zhou Zhou, 2019, Advances in Therapy.

Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States

A. Fischer, Zheng-Yi Zhou, Wenxi Tang, 2019, The Journal of Rheumatology.

Humanistic and cost burden of systemic sclerosis: A review of the literature.

N. Schoof, A. Fischer, D. Esser, 2017, Autoimmunity reviews.

The lung may play a role in the pathogenesis of rheumatoid arthritis.

A. Fischer, K. Deane, J. Solomon, 2014, International journal of clinical rheumatology.

Autoantibodies identified in rheumatoid arthritis and associations with the lung disease in rheumatoid arthritis

A. Fischer, K. Deane, J. Solomon, 2014 .

Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease.

T. Pincus, R. D. du Bois, K. Brown, 2010, Respiratory medicine.

Psychometric Validation of the Pulmonary Arterial Hypertension‐Symptoms and Impact (PAH‐SYMPACT) Questionnaire: Results of the SYMPHONY Trial

D. Badesch, M. Gomberg-Maitland, A. Fischer, 2018, Chest.

Exercise peripheral oxygen saturation (Spo2) accurately reflects arterial oxygen saturation (Sao2) and predicts mortality in systemic sclerosis

R. D. du Bois, K. Brown, S. K. Frankel, 2009, Thorax.

Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population

V. Steen, A. Fischer, M. Hinchcliff, 2011, The Journal of Rheumatology.

LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis

A. Fischer, B. Decato, S. Palmer, 2022, Respiratory Research.

Rheumatoid arthritis interstitial lung disease: Time to take notice

A. Fischer, J. Solomon, 2014, Respirology.

Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers

P. Ferrari, A. Fischer, S. Studer, 2013 .

Rebuttal From Drs Lee and Fischer.

A. Fischer, Joyce S. Lee, 2019, Chest.

POINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? Yes.

A. Fischer, Joyce S. Lee, 2019, Chest.

Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience.

K. Brown, A. Fischer, J. Swigris, 2016, Respiratory medicine.

Current approach to connective tissue disease-associated interstitial lung disease

A. Fischer, J. Solomon, S. Chartrand, 2014, Current opinion in pulmonary medicine.

Longitudinal assessment of interstitial pneumonia with autoimmune features is encouraged.

A. Fischer, S. Chartrand, Joyce S. Lee, 2017, Respiratory medicine.

Connective tissue disease-associated lung disease.

K. Brown, A. Fischer, A. Olson, 2012, Immunology and allergy clinics of North America.

Evaluating systemic lupus erythematosus patients for lung involvement

C. Hitchon, A. Fischer, H. El-Gabalawy, 2012, Lupus.

Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease

K. Brown, A. Fischer, J. Solomon, 2011, European Respiratory Journal.

FEV1 over time in patients with connective tissue disease-related bronchiolitis.

K. Brown, A. Fischer, J. Solomon, 2013, Respiratory medicine.

A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia

Jonathan H. Chung, A. Fischer, J. Swigris, 2016, The Journal of Rheumatology.

Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis.

R. D. du Bois, K. Brown, S. K. Frankel, 2009, Chest.

Pulmonary Fibrosis Predicts Survival in Patients With Idiopathic Heart Rate Recovery After 6-Min Walk Test

K. Brown, G. Cosgrove, A. Fischer, 2009 .

Psychometric Validation of the Pulmonary Arterial Hypertension Symptoms and Impact (PAH-SYMPACT®) Questionnaire

D. Badesch, M. Gomberg-Maitland, A. Fischer, 2016 .